267 related articles for article (PubMed ID: 21051559)
41. Increased prevalence of catecholamine excess and phaeochromocytomas in a well-defined Dutch population with SDHD-linked head and neck paragangliomas.
van Houtum WH; Corssmit EP; Douwes Dekker PB; Jansen JC; van der Mey AG; Bröcker-Vriends AH; Taschner PE; Losekoot M; Frölich M; Stokkel MP; Cornelisse CJ; Romijn JA
Eur J Endocrinol; 2005 Jan; 152(1):87-94. PubMed ID: 15762191
[TBL] [Abstract][Full Text] [Related]
42. Correlation between in vivo 18F-FDG PET and immunohistochemical markers of glucose uptake and metabolism in pheochromocytoma and paraganglioma.
van Berkel A; Rao JU; Kusters B; Demir T; Visser E; Mensenkamp AR; van der Laak JA; Oosterwijk E; Lenders JW; Sweep FC; Wevers RA; Hermus AR; Langenhuijsen JF; Kunst DP; Pacak K; Gotthardt M; Timmers HJ
J Nucl Med; 2014 Aug; 55(8):1253-9. PubMed ID: 24925884
[TBL] [Abstract][Full Text] [Related]
43. Advances in catecholamine and metabolite measurements for diagnosis of pheochromocytoma.
Rosano TG; Swift TA; Hayes LW
Clin Chem; 1991 Oct; 37(10 Pt 2):1854-67. PubMed ID: 1914202
[TBL] [Abstract][Full Text] [Related]
44. Plasma metanephrines and prospective prediction of tumor location, size and mutation type in patients with pheochromocytoma and paraganglioma.
Eisenhofer G; Deutschbein T; Constantinescu G; Langton K; Pamporaki C; Calsina B; Monteagudo M; Peitzsch M; Fliedner S; Timmers HJLM; Bechmann N; Fankhauser M; Nölting S; Beuschlein F; Stell A; Fassnacht M; Prejbisz A; Lenders JWM; Robledo M
Clin Chem Lab Med; 2020 Oct; 59(2):353-363. PubMed ID: 33001846
[TBL] [Abstract][Full Text] [Related]
45. Estimation of the cytoplasmic catecholamine concentrations in pheochromocytoma cells.
Perlman RL; Sheard BE
Biochim Biophys Acta; 1982 Nov; 719(2):334-40. PubMed ID: 6129902
[TBL] [Abstract][Full Text] [Related]
46. Biochemical tests for diagnosis of phaeochromocytoma: urinary versus plasma determinations.
Plouin PF; Duclos JM; Menard J; Comoy E; Bohuon C; Alexandre JM
Br Med J (Clin Res Ed); 1981 Mar; 282(6267):853-4. PubMed ID: 6783201
[TBL] [Abstract][Full Text] [Related]
47. Genetic predisposition to phaeochromocytoma: analysis of candidate genes GDNF, RET and VHL.
Woodward ER; Eng C; McMahon R; Voutilainen R; Affara NA; Ponder BA; Maher ER
Hum Mol Genet; 1997 Jul; 6(7):1051-6. PubMed ID: 9215674
[TBL] [Abstract][Full Text] [Related]
48. The VHL/HIF Axis in the Development and Treatment of Pheochromocytoma/Paraganglioma.
Peng S; Zhang J; Tan X; Huang Y; Xu J; Silk N; Zhang D; Liu Q; Jiang J
Front Endocrinol (Lausanne); 2020; 11():586857. PubMed ID: 33329393
[TBL] [Abstract][Full Text] [Related]
49. Ultrastructural and biochemical studies in phaeochromocytoma.
Barańska W; Wocial B; Januszewicz W
Acta Physiol Pol; 1982; 33(5-6):475-83. PubMed ID: 7186750
[TBL] [Abstract][Full Text] [Related]
50. Comparative study of plasma dopamine-beta-hydroxylase activities in noradrenaline-secreting and adrenaline-secreting phaeochromocytomae.
Aunis D; Bouclier M
Clin Exp Pharmacol Physiol; 1977; 4(4):359-63. PubMed ID: 908179
[TBL] [Abstract][Full Text] [Related]
51. Activation of RAS Signalling is Associated with Altered Cell Adhesion in Phaeochromocytoma.
Rossitti HM; Dutta RK; Larsson C; Ghayee HK; Söderkvist P; Gimm O
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33138083
[TBL] [Abstract][Full Text] [Related]
52. Perioperative outcomes of syndromic paraganglioma and pheochromocytoma resection in patients with von Hippel-Lindau disease, multiple endocrine neoplasia type 2, or neurofibromatosis type 1.
Butz JJ; Yan Q; McKenzie TJ; Weingarten TN; Cavalcante AN; Bancos I; Young WF; Schroeder DR; Martin DP; Sprung J
Surgery; 2017 Dec; 162(6):1259-1269. PubMed ID: 28919049
[TBL] [Abstract][Full Text] [Related]
53. Gene targeting through o-methylated catecholamine metabolite patterns.
Shine B
Clin Chem; 2011 Mar; 57(3):361-2. PubMed ID: 21245368
[No Abstract] [Full Text] [Related]
54. Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma.
Kimura N; Takayanagi R; Takizawa N; Itagaki E; Katabami T; Kakoi N; Rakugi H; Ikeda Y; Tanabe A; Nigawara T; Ito S; Kimura I; Naruse M;
Endocr Relat Cancer; 2014 Jun; 21(3):405-14. PubMed ID: 24521857
[TBL] [Abstract][Full Text] [Related]
55. Overnight excretion of urinary catecholamines and metabolites in the detection of pheochromocytoma.
Peaston RT; Lennard TW; Lai LC
J Clin Endocrinol Metab; 1996 Apr; 81(4):1378-84. PubMed ID: 8636337
[TBL] [Abstract][Full Text] [Related]
56. Effects of slow-release octreotide on urinary metanephrine excretion and plasma chromogranin A and catecholamine levels in patients with malignant or recurrent phaeochromocytoma.
Lamarre-Cliche M; Gimenez-Roqueplo AP; Billaud E; Baudin E; Luton JP; Plouin PF
Clin Endocrinol (Oxf); 2002 Nov; 57(5):629-34. PubMed ID: 12390337
[TBL] [Abstract][Full Text] [Related]
57. Plasma adrenomedullin concentrations in patients with adrenal pheochromocytoma.
Letizia C; De Toma G; Caliumi C; Cerci S; Massa R; Loria RD; Alo P; Marinoni EM; Diacinti D; D'Erasmo E
Horm Metab Res; 2001 May; 33(5):290-4. PubMed ID: 11440275
[TBL] [Abstract][Full Text] [Related]
58. Association Between Urinary Catecholamine Excretion and Urine Volume.
Haap M; Blaschka F; Lehmann R; Hoyer A; Müssig K
Horm Metab Res; 2019 Aug; 51(8):531-538. PubMed ID: 31174227
[TBL] [Abstract][Full Text] [Related]
59. Dietary influences on plasma and urinary metanephrines: implications for diagnosis of catecholamine-producing tumors.
de Jong WH; Eisenhofer G; Post WJ; Muskiet FA; de Vries EG; Kema IP
J Clin Endocrinol Metab; 2009 Aug; 94(8):2841-9. PubMed ID: 19567530
[TBL] [Abstract][Full Text] [Related]
60. 18F-FDOPA PET/CT Uptake Parameters Correlate with Catecholamine Secretion in Human Pheochromocytomas.
Moog S; Houy S; Chevalier E; Ory S; Weryha G; Rame M; Klein M; Brunaud L; Gasman S; Cuny T
Neuroendocrinology; 2018; 107(3):228-236. PubMed ID: 29949805
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
